Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes.

Loading...
Thumbnail Image

Date

2015-11

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

121
views
130
downloads

Citation Stats

Abstract

The burden of chronic hepatitis C virus (HCV) infection is significant and growing. HCV is considered one of the leading causes of liver disease worldwide and the leading cause of liver transplantation globally. While those infected is estimated in the hundreds of millions, this is likely an underestimation because of the indolent nature of this disease when first contracted. Approximately 20% of patients with HCV infection will progress to advanced fibrosis and cirrhosis. Those that do are at risk of decompensated liver disease including GI bleeding, encephalopathy, severe lab abnormalities, and hepatocellular carcinoma. Those individuals with advanced fibrosis and cirrhosis have historically been difficult to treat. The backbone of previous HCV regimens was interferon (IFN). The outcomes for IFN based regimens were poor and resulted in increased adverse events among those with advanced fibrosis and cirrhosis. Now, in the era of new direct acting antiviral (DAA's) medications, there is hope for curing chronic HCV in everyone, including those with advanced fibrosis and cirrhosis. This article provides a review on the most up to date data on the use of DAA's in patients with advanced fibrosis and cirrhosis. We are at a point where HCV could be truly eradicated, but to do so will require ensuring there are effective and safe treatments for those with advanced fibrosis and cirrhosis.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1177/2040622315603642

Publication Info

Wilder, Julius M, and Andrew J Muir (2015). Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis, 6(6). pp. 314–327. 10.1177/2040622315603642 Retrieved from https://hdl.handle.net/10161/12753.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Wilder

Julius Middleton Wilder

Associate Professor of Medicine
Muir

Andrew Joseph Muir

Professor of Medicine
  • Hepatitis C 
  • Primary sclerosing cholangitis
  • Cirrhosis
  • Liver Transplantation
  • Clinical Trials
  • Healthcare disparities in liver disease 
  • Outcomes Research

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.